Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis

Research output: Contribution to journalArticle

193 Citations (Scopus)

Abstract

The development of the luteinizing hormone-releasing hormone (LH-RH) agonists and antagonists and the principles of their clinical use were reviewed. In the 28 years that have elapsed since the elucidation of the structure of LH-RH, various applications in gynecology, reproductive medicine, and oncology have been established for LH-RH agonists and antagonists. These clinical applications are based on inhibition of the pituitary and the gonads. The advantage of the LH-RH antagonists is due to the fact that they inhibit the secretion of gonadotropins and sex steroids immediately after the first injection and thus achieve rapid therapeutic effects in contrast to the agonists, which require repeated administration. LH-RH antagonists should find applications in the treatment of benign gynecologic disorders and benign prostatic hypertrophy and in assisted reproduction programs. The primary treatment of advanced androgen-dependent prostate cancer is presently based on the use of depot preparations of LH-RH agonists, but antagonists like Cetrorelix already have been tried successfully. Antagonists of LH-RH might be more efficacious than agonists in treatment of patients with breast cancer as well as ovarian and endometrial cancer. Recently, practical cytotoxic analogs of LH-RH that can be targeted to LH-RH receptors on tumors have been synthesized and successfully tested in experimental cancer models. Targeted cytotoxic LH-RH analogs show a great promise for therapy of prostate, breast, and ovarian cancers.

Original languageEnglish
Pages (from-to)1247-1262
Number of pages16
JournalPeptides
Volume20
Issue number10
DOIs
StatePublished - Oct 1 1999
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Carcinogenesis
Hormone Antagonists
Ovarian Neoplasms
Prostatic Neoplasms
Gynecology
Breast Neoplasms
Delayed-Action Preparations
LHRH Receptors
Reproductive Medicine
Oncology
Prostatic Hyperplasia
Gonads
Therapeutic Uses
Therapeutics
Endometrial Neoplasms
Gonadotropins
Androgens
Medicine
Reproduction

Keywords

  • Breast and prostate cancer
  • Cytotoxic LH-RH analogs
  • Endometrial
  • LH-RH agonists and antagonists
  • Ovarian

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Luteinizing hormone-releasing hormone analogs : Their impact on the control of tumorigenesis. / Schally, Andrew V.

In: Peptides, Vol. 20, No. 10, 01.10.1999, p. 1247-1262.

Research output: Contribution to journalArticle

@article{54b6a5fead764b288d65e7f59885cf65,
title = "Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis",
abstract = "The development of the luteinizing hormone-releasing hormone (LH-RH) agonists and antagonists and the principles of their clinical use were reviewed. In the 28 years that have elapsed since the elucidation of the structure of LH-RH, various applications in gynecology, reproductive medicine, and oncology have been established for LH-RH agonists and antagonists. These clinical applications are based on inhibition of the pituitary and the gonads. The advantage of the LH-RH antagonists is due to the fact that they inhibit the secretion of gonadotropins and sex steroids immediately after the first injection and thus achieve rapid therapeutic effects in contrast to the agonists, which require repeated administration. LH-RH antagonists should find applications in the treatment of benign gynecologic disorders and benign prostatic hypertrophy and in assisted reproduction programs. The primary treatment of advanced androgen-dependent prostate cancer is presently based on the use of depot preparations of LH-RH agonists, but antagonists like Cetrorelix already have been tried successfully. Antagonists of LH-RH might be more efficacious than agonists in treatment of patients with breast cancer as well as ovarian and endometrial cancer. Recently, practical cytotoxic analogs of LH-RH that can be targeted to LH-RH receptors on tumors have been synthesized and successfully tested in experimental cancer models. Targeted cytotoxic LH-RH analogs show a great promise for therapy of prostate, breast, and ovarian cancers.",
keywords = "Breast and prostate cancer, Cytotoxic LH-RH analogs, Endometrial, LH-RH agonists and antagonists, Ovarian",
author = "Schally, {Andrew V}",
year = "1999",
month = "10",
day = "1",
doi = "10.1016/S0196-9781(99)00130-8",
language = "English",
volume = "20",
pages = "1247--1262",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Luteinizing hormone-releasing hormone analogs

T2 - Their impact on the control of tumorigenesis

AU - Schally, Andrew V

PY - 1999/10/1

Y1 - 1999/10/1

N2 - The development of the luteinizing hormone-releasing hormone (LH-RH) agonists and antagonists and the principles of their clinical use were reviewed. In the 28 years that have elapsed since the elucidation of the structure of LH-RH, various applications in gynecology, reproductive medicine, and oncology have been established for LH-RH agonists and antagonists. These clinical applications are based on inhibition of the pituitary and the gonads. The advantage of the LH-RH antagonists is due to the fact that they inhibit the secretion of gonadotropins and sex steroids immediately after the first injection and thus achieve rapid therapeutic effects in contrast to the agonists, which require repeated administration. LH-RH antagonists should find applications in the treatment of benign gynecologic disorders and benign prostatic hypertrophy and in assisted reproduction programs. The primary treatment of advanced androgen-dependent prostate cancer is presently based on the use of depot preparations of LH-RH agonists, but antagonists like Cetrorelix already have been tried successfully. Antagonists of LH-RH might be more efficacious than agonists in treatment of patients with breast cancer as well as ovarian and endometrial cancer. Recently, practical cytotoxic analogs of LH-RH that can be targeted to LH-RH receptors on tumors have been synthesized and successfully tested in experimental cancer models. Targeted cytotoxic LH-RH analogs show a great promise for therapy of prostate, breast, and ovarian cancers.

AB - The development of the luteinizing hormone-releasing hormone (LH-RH) agonists and antagonists and the principles of their clinical use were reviewed. In the 28 years that have elapsed since the elucidation of the structure of LH-RH, various applications in gynecology, reproductive medicine, and oncology have been established for LH-RH agonists and antagonists. These clinical applications are based on inhibition of the pituitary and the gonads. The advantage of the LH-RH antagonists is due to the fact that they inhibit the secretion of gonadotropins and sex steroids immediately after the first injection and thus achieve rapid therapeutic effects in contrast to the agonists, which require repeated administration. LH-RH antagonists should find applications in the treatment of benign gynecologic disorders and benign prostatic hypertrophy and in assisted reproduction programs. The primary treatment of advanced androgen-dependent prostate cancer is presently based on the use of depot preparations of LH-RH agonists, but antagonists like Cetrorelix already have been tried successfully. Antagonists of LH-RH might be more efficacious than agonists in treatment of patients with breast cancer as well as ovarian and endometrial cancer. Recently, practical cytotoxic analogs of LH-RH that can be targeted to LH-RH receptors on tumors have been synthesized and successfully tested in experimental cancer models. Targeted cytotoxic LH-RH analogs show a great promise for therapy of prostate, breast, and ovarian cancers.

KW - Breast and prostate cancer

KW - Cytotoxic LH-RH analogs

KW - Endometrial

KW - LH-RH agonists and antagonists

KW - Ovarian

UR - http://www.scopus.com/inward/record.url?scp=0032739426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032739426&partnerID=8YFLogxK

U2 - 10.1016/S0196-9781(99)00130-8

DO - 10.1016/S0196-9781(99)00130-8

M3 - Article

C2 - 10573298

AN - SCOPUS:0032739426

VL - 20

SP - 1247

EP - 1262

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 10

ER -